Judith Nelissen
Vice President & Head of Global Value Evidence Astellas Pharma
Judith Nelissen is a leading authority in global value evidence strategy, shaping how real-world insights drive commercial decision-making, access success, and patient impact. With deep expertise spanning health economics, market access, and integrated evidence planning, she leads Astellas’ efforts to generate robust, actionable RWE that strengthens value communication across the product lifecycle. Judith is recognized for her rigorous yet pragmatic approach to quantifying evidence impact, moving beyond traditional activity metrics to frameworks that influence launch readiness, HTA outcomes, clinician confidence, and sustained product performance. Passionate about elevating the role of evidence in strategic planning, she continues to champion cross-functional alignment to unlock greater value for patients and healthcare systems.
Seminars
- Understanding how to overcome role confusion and shifting responsibilities in cross-functional RWE projects by embedding robust IEP governance
- Exploring frameworks to balance standardisation and agility, ensuring continuity despite team turnover or organisational change
- Gaining strategies to prioritise projects effectively, align evidence generation with stakeholder needs, and prevent duplication of efforts across functions
- Incorporating AI in the development of integrated evidence plans – what are the pros and cons and how can we move forward?
- Discover why traditional project-level metrics (e.g. number of studies, publications) fall short in capturing the true impact of RWE functions
- Benchmark emerging approaches to evaluate how evidence planning contributes to launch readiness, market access, and clinical decision-making
- Learn practical strategies to capture long-term impact from shaping prescriber behaviour to influencing HTA/payer decisions, despite gaps in unbiased, representative datasets
